1. Asahina H, Yamazaki K, Kinoshita I et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95: 998–1004.
2. Burton A. What went wrong with Iressa? Lancet Oncol 2002; 3: 708.
3. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160–74.
4. Comis RL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005; 10: 467–70.
5. Imyanitov EN, Suspitsin EN, Buslov KG et al. Isolation of nucleic acids from paraffin-embedded archival tissues and other difficult sources. In: J.Kieleczawa (ed). The DNA Book: Protocols and Procedures for the Modern Molecular Biology Laboratory. Sudbury, MA, Jones and Bartlett Publishers, 2006; p. 85–97.
6. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapynaive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340–6.
7. Inoue A, Kobayashi K, Usui K et al. North East Japan Gefitinib Study Group: North East Japan Gefitinib Study Group: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394–400.
8. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39.
9. Marchetti A, Martella C, Felicioni L et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857–65.
10. Mitsudomi T, Morita S, Yatabe Y et al.; for the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8.
11. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.
12. Morita S, Okamoto I, Kobayashi K et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15: 4493–8.
13. Paez JG, Jаnne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500.
14. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306–11.
15. Pinter F, Papay J, Almasi A et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008; 10: 160–8.
16. Rosell R, Moran T, Queralt C et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958–67.
17. Schmid K, Oehl N, Wrba F et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554–60.
18. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587–95.
19. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442–9.
20. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–46.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
22. Tsuboi M, Kato H, Nagai K et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005; 16: 1123–8.
23. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006; 23: 61–170.
24. Wu JY, Yu CJ, Yang CH et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008; 178: 847–53.
25. Wu JY, Shih JY, Yang CH et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010; 126: 247–55.
26. Yang CH, Yu CJ, Shih JY et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745–53.
27. Zhang X, Chang A. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer: J Med Genet 2007; 44: 166–72.

В.М.Моисеенко, С.А.Проценко, И.И.Семенов, Ф.В.Моисеенко, Е.В.Левченко,
Д.E.Мацко, А.О.Иванцов, А.Г.Иевлева, Н.В.Митюшкина, А.В.Того, Е.Н.Имянитов

НИИ онкологии им. Н.Н.Петрова, Санкт-Петербург